Baird Upgrades Teladoc to Outperform - $TDOCBaird analyst Matthew Gillmor upgraded Teladoc (NYSE: TDOC) from Neutral to Outperform with a price target of $80.00. The analyst comments "With the stock down ~40% off 2018 highs we now think valuation is more attractive. Additionally, we think there will be several positive catalysts during 1H19 including: (1) potential for guidance to be in-line/above Street estimates; (2) Medicare Advantage sales ahead of June biding deadlines; and (3) positive announcements re: UNH penetration."* This stock has been on our trading list for a while now. Will continue to look for trades in this name. * Tiger's Take: "The next big thing for health-care and currently on sale." $TDOC, Teladoc Health, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or posts.